文献速递心力衰竭与心肌病

2周酮酯治疗在2型糖尿病合并射血分数保留心衰患者的随机交叉试验

Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · Circulation · 2024-08-20

该研究为6周随机双盲交叉试验,24例2型糖尿病合并射血分数保留心衰患者接受2周口服酮酯(25g D-β-羟基丁酸-(R)-1,3-丁二醇,每日4次)及等热量等体积安慰剂。结果显示酮酯治疗使4小时静息期心输出量增加0.2 L/min,降低静息及运动峰值肺毛细血管楔压,并改善压力-流量关系。

要点

  • 酮酯治疗2周可增加心输出量并降低心脏充盈压。
  • 运动峰值肺毛细血管楔压降低5 mmHg,压力-流量关系改善。
  • 酮酯右移左室舒张末压-容积关系,提示左室僵硬度降低。

核心结论

  • 在2型糖尿病合并射血分数保留心衰患者中,2周口服酮酯治疗增加心输出量、降低心脏充盈压和心室僵硬度。

研究设计与样本

  • 随机、双盲、交叉研究,共24例2型糖尿病合并射血分数保留心衰患者完成6周研究。
  • 患者接受2周酮酯治疗(25 g D-β-羟基丁酸-(R)-1,3-丁二醇,每日4次)和等热量等体积安慰剂,间隔2周洗脱期。

主要发现

  • 4小时静息期酮酯治疗后循环3-羟基丁酸水平为1010±56 µmol/L,安慰剂为91±55 µmol/L(P<0.001)。
  • 与安慰剂相比,酮酯治疗4小时期间心输出量增加0.2 L/min(95% CI,0.1至0.3)。
  • 酮酯治疗降低静息肺毛细血管楔压1 mmHg(95% CI,-2至0),降低运动峰值肺毛细血管楔压5 mmHg(95% CI,-9至-1)。
  • 酮酯治疗显著降低运动期间压力-流量关系(Δ肺毛细血管楔压/Δ心输出量)(P<0.001),并增加运动峰值每搏输出量10 mL(95% CI,0至20)。
  • 酮酯右移左室舒张末压-容积关系,提示左室僵硬度降低和顺应性改善。

临床怎么用

  • 对于2型糖尿病合并射血分数保留心衰患者,口服酮酯可能作为改善血流动力学的新治疗方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major cause of morbidity and mortality in patients with type 2 diabetes (T2D). Acute increases in circulating levels of ketone body 3-hydroxybutyrate have beneficial acute hemodynamic effects in patients without T2D with chronic heart failure with reduced ejection fraction. However, the cardiovascular effects of prolonged oral ketone ester (KE) treatment in patients with T2D and HFpEF remain unknown. METHODS: A total of 24 patients with T2D and HFpEF completed a 6-week randomized, double-blind crossover study. All patients received 2 weeks of KE treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily) and isocaloric and isovolumic placebo, separated by a 2-week washout period. At the end of each treatment period, patients underwent right heart catheterization, echocardiography, and blood samples at trough levels of intervention, and then during a 4-hour resting period after a single dose. A subsequent second dose was administered, followed by an exercise test. The primary end point was cardiac output during the 4-hour rest period. RESULTS: During the 4-hour resting period, circulating 3-hydroxybutyrate levels were 10-fold higher after KE treatment (1010±56 µmol/L; P<0.001) compared with placebo (91±55 µmol/L). Compared with placebo, KE treatment increased cardiac output by 0.2 L/min (95% CI, 0.1 to 0.3) during the 4-hour period and decreased pulmonary capillary wedge pressure at rest by 1 mm Hg (95% CI, -2 to 0) and at peak exercise by 5 mm Hg (95% CI, -9 to -1). KE treatment decreased the pressure-flow relationship (∆ pulmonary capillary wedge pressure/∆ cardiac output) significantly during exercise (P<0.001) and increased stroke volume by 10 mL (95% CI, 0 to 20) at peak exercise. KE right-shifted the left ventricular end-diastolic pressure-volume relationship, suggestive of reduced left ventricular stiffness and improved compliance. Favorable hemodynamic responses of KE treatment were also observed in patients treated with sodium-glucose transporter-2 inhibitors and glucagon-like peptide-1 analogs. CONCLUSIONS: In patients with T2D and HFpEF, a 2-week oral KE treatment increased cardiac output and reduced cardiac filling pressures and ventricular stiffness. At peak exercise, KE treatment markedly decreased pulmonary capillary wedge pressure and improved pressure-flow relationship. Modulation of circulating ketone levels is a potential new treatment modality for patients with T2D and HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05236335.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gopalasingam, Berg-Hansen, Christensen, et al. Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Circulation. 2024. PMID: 39162035. doi:10.1161/CIRCULATIONAHA.124.069732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。